# Somatrogon (Ngenla)

> Long-acting recombinant human growth hormone for pediatric GH deficiency — weekly dosing.

Source: https://peptides.cafe/peptide/somatrogon
Category: GH Analog · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
A long-acting recombinant fusion protein of human growth hormone with three copies of the C-terminal peptide (CTP) of hCG beta-subunit, extending half-life and enabling once-weekly subcutaneous dosing instead of daily.

## Research areas
- Pediatric growth hormone deficiency

## Common research protocols
- Weekly SC injection: Once-weekly subcutaneous injection; weight-based dosing.

## Study summaries
- "Phase 3 weekly somatrogon vs daily somatropin in children with GHD" — JCEM (2022): Non-inferior annual height velocity at 12 months with significantly better treatment-burden scores.

## Considerations
- FDA-approved June 2023.
- Same class warnings as daily GH (intracranial hypertension, glucose effects, scoliosis progression).
- Injection-site reactions common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.